Bell v. Boehringer Ingelheim Pharmaceuticals, Inc. et al
| Andrew Bell |
| Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi- Aventis U.S., LLC, Pfizer, Inc. and GlaxoSmithKline, LLC |
| 1:2021cv24376 |
| December 16, 2021 |
| US District Court for the Southern District of Florida |
| Personal Inj. Prod. Liability |
| 28 U.S.C. ยง 1332 |
| Plaintiff |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 16, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 2 Clerks Notice to Filer re: Electronic Case. Case administratively closed - Wrong Venue selected by Filer. CASE HAS BEEN RENUMBERED, the new case number is 21cv82491. No further entries will be made on this case. (amb) |
| Filing 1 COMPLAINT SHORT FORM COMPLAINT against Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, LLC, Pfizer, Inc., Sanofi- Aventis U.S., LLC. Filing fees $ 402.00 receipt number AFLSDC-15255463, filed by Andrew Bell. (Attachments: #1 Civil Cover Sheet)(Haberman, Jeffrey) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Florida Southern District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
